The post STX Technical Analysis Feb 10 appeared on BitcoinEthereumNews.com. STX shows neutral momentum at RSI 40.77 level, confirming short-term bearish pressureThe post STX Technical Analysis Feb 10 appeared on BitcoinEthereumNews.com. STX shows neutral momentum at RSI 40.77 level, confirming short-term bearish pressure

STX Technical Analysis Feb 10

STX shows neutral momentum at RSI 40.77 level, confirming short-term bearish pressure with MACD’s negative histogram and positioning below EMA20; volume decline reinforces trend weakness.

Trend Status and Momentum Analysis

STX is trading at 0.26 dollars as of February 10, 2026, with a 3.47% decline in the last 24 hours, keeping the daily range limited between 0.25-0.27 dollars. Volume is moving at low levels of 14.24 million dollars, confirming the weakness in momentum. The overall trend direction is downward; the price remains below EMA20 (0.28 dollars) and the Supertrend indicator gives a bearish signal, with resistance clearly emerging at 0.35 dollars. In the confluence of momentum oscillators, RSI is wandering in the neutral zone, while the negative expansion of the MACD histogram increases selling pressure. In multi-timeframe (MTF) analysis, 13 strong levels were detected on 1D, 3D, and 1W charts: 2 supports/3 resistances on 1D, 2 supports/1 resistance on 3D, and 2 supports/4 resistances on 1W. This structure indicates the possibility of consolidation or a deeper pullback in the short term. Main supports are concentrated at 0.2527 (score 76/100) and 0.2208 (76/100), while resistances are at 0.2704 (68/100), 0.2984 (69/100), and 0.3368 (61/100). Lack of volume confirmation limits the trend’s strength, and selling tendency dominates in accumulation/distribution patterns.

RSI Indicator: Buy or Sell?

RSI Divergence Analysis

RSI (14) is at 40.77 level and positioned in the neutral zone (between 30-70), approaching the oversold (below 30) threshold but not yet reaching it. No regular bearish divergence is observed on the daily chart; since RSI stays at similar levels while price makes new lows, hidden bullish divergence potential is low. However, on the 4-hour timeframe, RSI reacting to the price bottom at 0.25 dollars without dropping to 35 can be monitored as a potential hidden bullish divergence signal – but it remains weak without volume confirmation. Weekly RSI is around 45 and neutrality dominates in the long-term trend; price may need to test the 0.22 support for divergence formation. Overall, RSI shows slowdown in momentum but does not produce a sell signal; bullish confirmation should be sought above 50.

Oversold/Overbought Zones

RSI at 40.77 is close to the oversold zone but not yet triggered. Historically, when STX’s RSI drops below 30, rebounds are seen, but in the current downtrend, this level may signal deep selling. The overbought zone above 70 is distant; it had risen to 65 in recent rallies but pulled back quickly. In momentum confluence, RSI shows a bearish tilt in line with MACD.

MACD Signals and Histogram Dynamics

MACD status is clearly bearish: Histogram is expanding in the negative zone, signal line remains below the MACD line. On the daily chart, the last crossover was downward and histogram bars are lengthening, confirming acceleration in selling momentum. Slight contraction of the histogram on 4-hour indicates short-term slowdown signal, but staying below the zero line prevents trend reversal. No divergence; histogram negativity progresses in parallel with price decline. Negative histogram supported by volume strengthens the distribution pattern. For a bullish signal, histogram should approach zero and turn positive – unlikely in the current structure.

EMA Systems and Trend Strength

Short-Term EMAs

Price is below EMA20 (0.28 dollars), confirming short-term bearish bias. Narrowing between EMA10 and EMA20 ribbon shows momentum loss; price dropping below the ribbon accelerated sales. Daily closes could not approach EMA50 (around 0.29), trend strength is weak.

Medium/Long-Term EMA Supports

EMA50 and EMA200 ribbon is downward sloping, price below both. Medium-term EMA100 (around 0.31) is acting as resistance. No squeeze formation in ribbon dynamics; expanding bearish ribbon supports the downtrend. Breaking EMA200 (above 0.35) is required for long-term recovery, unlikely with current momentum. Check detailed charts for STX Spot Analysis and STX Futures Analysis.

Bitcoin Correlation

Bitcoin is in downtrend at 69,447 dollars level with 2.25% decline; main supports at 68,343, 62,910, and 46,196 dollars. Resistances at 70,938, 77,357, and 85,375. BTC Supertrend gives bearish signal and rising dominance poses risk for altcoins. STX is highly correlated with BTC (0.85+); if BTC breaks 68K support, STX could accelerate to 0.22. If BTC passes 70K resistance, breathing room may emerge for STX, but current BTC weakness suppresses altcoin momentum. Key BTC levels: Support breakdown will trigger STX sales.

Momentum Result and Expectations

In momentum oscillators confluence, RSI neutrality, MACD negative histogram, and EMA ribbon bearish tilt keep STX weak in short-medium term. Even without volume confirmation, MTF levels make 0.2527 support critical; on breakdown, 0.2208 is targeted. For bullish scenario, 0.2704/0.2984 resistances must be surpassed, bullish target 0.4528 (28 points). Overall outlook is cautious bearish; long positions risky without RSI dropping below 30 or MACD histogram contraction. Momentum is weak in trend strength measurement, volume increase expected. Market volatility high, monitor levels.

This analysis uses the market views and methodology of Chief Analyst Devrim Cacal.

Strategy Analyst: David Kim

Macro market analysis and portfolio management

This analysis is not investment advice. Do your own research.

Source: https://en.coinotag.com/analysis/stx-technical-analysis-february-10-2026-rsi-macd-momentum

Market Opportunity
Stacks Logo
Stacks Price(STX)
$0.2549
$0.2549$0.2549
-2.22%
USD
Stacks (STX) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26